BPHC Bulletin: FDA and CDC Lift Recommended Pause on Janssen (Johnson & Johnson) COVID-19 Vaccine

Date: April 27, 2021

1:00 PM-2:00 PM CST

Click here to Join the day of the session

Following a thorough safety review, including two meetings of the Centers for Disease Control and Prevention’s (CDC) Advisory Committee on Immunization Practices, the Food and Drug Administration (FDA) and CDC have determined that the recommended pause regarding the use of the Janssen (Johnson & Johnson) COVID-19 vaccine in the U.S. should be lifted and use of the vaccine should resume.

The full media advisory recommends that providers, vaccine recipients, and vaccine caregivers review these revised resources:

CDC’s Clinician Outreach and Communication Activity (COCA) Call will present the latest evidence on thrombosis with thrombocytopenia syndrome (TTS) after administration of the Janssen (Johnson & Johnson) COVID-19 vaccine. Speakers will discuss information on TTS and updated vaccine recommendations.